Results 121 to 130 of about 16,492 (195)

Unveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis. [PDF]

Medicine (Baltimore)
Du W, Li D, Li N, Zhang W, Wang J, Wang T, Zeng Y.   +6 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease. [PDF]

Atheroscler Plus
Ugovšek S, Rehberger Likozar A, Levstek T, Trebušak Podkrajšek K, Zupan J, Marka F, Trimmel T, Brekalo M, Speidl W, Hohensinner P, Haider P, Šebeštjen M.   +11 more
europepmc   +1 more source

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer.

JAMA Netw Open
Lu CA, Jiang C, Wang AZ, Zhang T.
europepmc   +1 more source

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]

Sci Rep
Dermiki-Gkana F, Gravel CA, Kontogiorgis C, Douros A.   +3 more
europepmc   +1 more source

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.

JAMA Netw Open
Kellogg C, Badillo Goicoechea E, Kim DD, Yaghi S, Chaturvedi S, Mehendale R, Orjuela K, Kass-Hout T, Morsi RZ, Morales J, Singh E, Jhaveri A, Prabhakaran S, Smith MM, Brorson JR, Golani S, Mazuera S, Kang R, Eltatawy A, Pillajo J, Siegler JE.   +20 more
europepmc   +1 more source

Clinical effect of proprotein convertase subtilisin/kexin type 9 inhibition in patients undergoing coronary artery bypass surgery. [PDF]

JTCVS Open
Nasso G, Marchese A, Santarpino G, Vignaroli W, Calabrese V, Taverna G, Larosa C, Bartolomucci F, Fiore F, Brigiani MS, Contegiacomo G, Greco E, Speziale G.   +12 more
europepmc   +1 more source

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes. [PDF]

Front Med (Lausanne)
Zhou Q, Liu X, Tang Y, Pan C, Bi X.
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity-Matched Cohort Study. [PDF]

Clin Pharmacol Ther
Nardi Agmon I, Gurevitz C, Shochat T, Kushnir S, Witberg G, Levi A, Gilon D, Kornowski R, Thavendiranathan P, Abdel Qadir H, Iakobishvili Z.   +10 more
europepmc   +1 more source

Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Adv Ther
Masson W, Lobo M, Giunta G, Barbagelata L, Nogueira JP.   +4 more
europepmc   +1 more source

Dramatic Coronary Artery Aneurysm Regression After Coronary Artery Bypass Grafting and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. [PDF]

Interdiscip Cardiovasc Thorac Surg
Yokoyama Y, Higashino H, Fujieda H, Abe M.   +3 more
europepmc   +1 more source